BioSpace News Archive

Bristol Myers Squibb (NYSE: BMY) will announce results for the fourth quarter of 2023 on Friday, February 2, 2024.

Abeona Therapeutics Inc. announced it has granted equity awards to new non-executive employees who joined the Company.

Immusoft of CA, a wholly owned subsidiary of Immusoft Corporation (“Immusoft”), a clinical-stage cell therapy company dedicated to improving the lives of patients with rare diseases, today announced the first patient dosed with engineered B cell therapy ISP-001 in a Phase 1 trial in MPS I, at M Health Fairview University of Minnesota Medical Center.

Finacity Corporation announced that it has successfully launched a trade receivables securitization for Laboratorios Sanfer, S.A. de C.V.

Curia, a leading contract research, development and manufacturing organization, announced that Gerald Auer has been appointed as chief financial officer.

Halia Therapeutics today announced that the company will present at the 13th World Gastroenterology, IBD & Hepatology Conference taking place during December 15-17, 2023, in Dubai, United Arab Emirates and virtually.

Totus Medicines, a company revolutionizing small molecule drug discovery and development using covalent libraries and AI tools, announced that Nassim Usman, Ph.D., has been named President & Chief Executive Officer and closed a $66M Series B financing led by DCVC Bio.

Vizgen, Inc. announced that five of the ten studies published in the December 13 issue of Nature, which unveiled the first full cellular map of the adult mouse brain, leveraged MERFISH technology for spatial genomics insights.

Abbott announced that its board of directors has increased the company’s quarterly common dividend to 55 cents per share, an increase of 7.8%.

Biosenta Inc. (CSE: ZRO) (“Biosenta” or the “Company”) is pleased to announce a non-brokered private placement financing (the “Offering”) of 1,250,000 units of the Company (the “Units”), for aggregate gross proceeds of $500,000.